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Material and Methods: Patients with histologically confirmed 
rectal adenocarcinoma who were treated with preoperative 
RCT and TME between January 2000 and December 2014 were 
retrospectively included. Patients who received no 
preoperative RCT, patients treated with postoperative RCT 
and those treated for a local recurrence were excluded. 
Following pretreatment clinical characteristics were 
extracted from the medical files: age, gender, body mass 
index, ASA score, cT-stage, cN-stage, tumor distance from 
the anal verge, pretreatment CEA, pretreatment hemoglobin 
and distance from the mesorectal fascia. Univariable and 
multivariable binary logistic regression models were used to 
predict pCR and ypT0-1N0. A multivariable prediction model 
was obtained by combining all predictors and by applying a 
backward selection procedure with 0.157 as critical level for 
the p-value. The discriminative ability of the prediction 
models was evaluated by receiver operating characteristic 
analysis.To avoid that the same data were used to develop 
and to validate the model, the area under the curve (AUC) 
was based on a leave-one out cross-validation. 
 
Results: A total of 620 patients were included of whom 120 
patients experienced a pCR (19%) and 170 patients achieved a 
ypT0-1N0 response (27%). A low pretreatment CEA, a high 
pretreatment hemoglobin and a high cN-stage were 
associated with pCR in multivariable analysis (Table). A low 
pretreatment CEA, a low cT-stage and a high cN-stage were 
associated with ypT0-1N0. After cross-validation, the AUC of 
the pCR and ypT0-1N0 prediction model equaled 0.609 and 
0.632, respectively. 
 
 
Conclusion: Despite their statistical significance, the value of 
pretreatment clinical variables in the prediction of pCR and 
ypT0-1N0 is very limited. To safely select rectal cancer 
patients for organ-preservation, other strategies using 
functional imaging or molecular markers need to be 
explored. 
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Purpose or Objective: The relationship between radiation 
therapy for rectal cancer and secondary malignancies is 
debated. The present study is the first population-based 
analysis using conventional multivariable analyses as well as 
propensity score matching to assess this relationship. 
 
Material and Methods: Overall, 87,956 patients after 
resection of localized or locally advanced rectal 
adenocarcinoma diagnosed between 1973 and 2012 were 
identified in the Surveillance, Epidemiology, and End Results 
(SEER) registry. The occurrence of secondary malignancies 
diagnosed at least 1 year after diagnosis of rectal cancer was 
compared in patients who did and did not undergo radiation 
using adjusted and propensity score matched Cox regression 
analysis. 
 
Results: Of 77,484 patients, 34,114 underwent radiation and 
43,370 did not. Overall, radiation therapy was not associated 
with secondary malignancies (hazared ratio [HR] = 0.97 
(95%CI: 0.92−1.02, P=0.269). In female patients (HR = 1.11, 
95%CI:1.02−1.21, P=0.021) the risk for secondary 
malignancies was increased after radiation therapy, while a 
decrease of secondary maligancies was found in male 
patients (HR = 0.90, 95%CI:0.85−0.96, P=0.002). The risk for 
prostate cancer was significantly decreased (HR=0.44, 
95%CI:0.38−0.51, P<0.001) whereas the risk for endometrial 
cancer was increased (HR=2.07, 95%CI:1.56−2.75, P<0.001). 
The risks for lung cancer (HR=1.20, 95%CI:1.08−1.34, 
P<0.001), bladder cancer (HR=1.50, 95%CI:1.26−1.77, 
P<0.001), and lymphoma (HR=1.29, 95%CI:1.02−1.62, 
P=0.032) were increased after radiation in the overall 
population. 
 
Conclusion: The present analysis provides compelling 
evidence regarding gender-specific differences in the 
occurence of secondary malignancies after pelvic radiation. 
Indeed, radiation for rectal cancer is associated with a 
significantly decreased risk of prostate cancer, however, an 
increased risk of endometrial, lung, and bladder cancer as 
well as lymphoma. Patients undergoing radiation for rectal 
cancer must be informed regarding the potentially increased 
risk of secondary malignancies. 
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Purpose or Objective: The purpose of the study is to look at 
the benefit of administration of an oral prebiotic starch in 
reducing the incidence of acute radiation proctitis, a 
distressing symptom in patients receiving radiation therapy 
for cancer of the cervix. 
Material and Methods: The study was conducted between 
2011 and 2014 in 104 patients receiving radical chemo-
radiotherapy for carcinoma cervix. Patients were randomized 
to two arms receiving 30 gm of resistant starch or digestible 
starch on a daily basis through out the course of the external 
radiotherapy. All patients received standard 4-field box 
radiation portals, 50 Gy in 25 fractions with 4 cycles of 
weekly concurrent Cisplatin. All of them underwent LDR 
brachytherapy of 30 Gy at completion of external beam 
radiotherapy. The study was double blinded and allocation 
was concealed from the investigators. The investigator 
recorded the radiotherapy related toxicity of the patients 
according to CTC V 3.0. The incidence and severity of grade 
2-4 diarrhoea and proctitis were documented on a weekly 
basis and compared across the two randomized groups and 
analysed. Stool short chain fatty acid concentrations were 
measured at baseline at 2nd and 4th week and after 6 weeks 
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of completion of radiotherapy in both study arm and placebo 
arm and reported. 2 patients progressed during therapy and 
were not included in analyses and two patients discontinued 
the intervention. A per protocol analyses was done. 
 
 
Results: At analysis there were 50 patients in each arm. The 
severity of clinical proctitis was found to be similar in both 
groups of patients with 12.2 % of patients experiencing 
toxicity of grade 2 and above in digestible starch group 
versus 14.6% in the resistant starch group. Functional 
proctitis was similarly graded and it was found that 16.3 % 
patients in digestible starch group experienced toxicity 
against 10.2 % patients in the amylase resistant starch group. 
This difference was seen at 4th week and continued in the 
subsequent weeks till the end of radiation. Both groups had 
similar reported toxicity at 6 weeks post intervention. Both 
groups were also found to have similar incidence of grade 2 
and above diarrhea. The non-digestible starch group was 
found to have 8% incidence as compared to 2% in the other 
group at the 5th and 6th week. The short chain fatty acid 
concentrations were found to be not significantly different in 
the groups at any point. 
 
 
Conclusion: The study failed to demonstrate a benefit in 
administration of resistant starch in excess of normal diet to 
patients receiving pelvic radiotherapy. This may be 
postulated to be due to concurrent use of chemotherapy and 
decrease in intestinal probiotics. 
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Purpose or Objective: To compare treatment outcomes in 
locally advanced cervical carcinoma (LACC) patients treated 
with neoadjuvant chemoradiation followed by radical surgery 
(surgery group: SG) versus radical chemoradiation plus 
brachytherapy boost (control group: CG). Results in terms of 
local control (LC), metastases-free survival (MFS), disease 
free survival (DFS) and overall survival (OS) were compared. 
 
Material and Methods: Seventy-six patients with LACC (SG) 
were matched to 76 patients (CG) with respect to age, 
histology and stage. Matching was performed without 
knowledge of outcomes. Patients characteristics are 
summarized in Table 1. The median FU was 35 months 
(range: 2-107) for SG and 29 months (range: 1-125) for CG, 
respectively. 
 
 
Results: At univariate analysis no significant differences 
between the two groups were recorded. Two-year and 5-year 
LC were 77.6% and 71.0% for SG and 76.1% and 70.3% for CG 
(p=0.8), respectively. Two-year and 5-year MFS were 79.3% 
and 70.8% for SG and 78.8% and 78.8% for CG (p=0.6), 
respectively. Two-year and 5-year DFS were 71.9% and 61.6% 
for SG and 66.1% and 61.0% for CG (p=0.8), respectively. 
Two-year and 5-year OS were 90.9% and 84.4% for SG and 
90.3% and 69.9% for CG (p=0.4), respectively. 
 
Conclusion: The two treatment approaches achieved 
comparable outcomes in patients with locally advanced 
cervical carcinoma. Further analyses are needed to compare 
the toxicity profile of these two treatment strategies. 
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MR-PET is an advanced hybrid imaging method giving both 
structural, functional, molecular and biochemical information 
simultaneously or almost simultaneously. There are still 
challenges, not only with the attenuation correction, but also 
with performance of the examination and timing of the MR 
and PET acquisition.  
